NCT06523621View on ClinicalTrials.gov

Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 28, 2025

Primary Completion Date

November 30, 2027

Study Completion Date

November 30, 2027

Conditions
Multiple Myeloma
Interventions
DRUG

Nivolumab

2 cycles of nivolumab at a dose of 480 mg given over approximately 30-minutes intravenously on Day 1 of each treatment cycle

Trial Locations (2)

27103

RECRUITING

Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem

28204

RECRUITING

Levine Cancer Institute, Charlotte

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Atrium Health Levine Cancer Institute

OTHER

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Wake Forest University Health Sciences

OTHER

NCT06523621 - Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel | Biotech Hunter | Biotech Hunter